All sectors need to deal with sustainability and the life science industry is no exception. As regulations are tightening in many countries, working on your sustainability profile has moved from a ’nice to do’ to a ’must do’ for companies within biotech, pharma and medtech, regardless of size. But there is also a pure business case for stepping up your game in the sustainability arena, as we will hear in this session. Not least since investors are increasingly evaluating life science companies on this parameter when they make their pick. If you want the money, and the strategic partnerships, you better work on that sustainability plan. But what exactly is that and what are investors looking for?

With our moderator, Ann Margrethe Platou, Analyst at DNB, and speakers from leading actors from the investors’ scene, this session will give some concrete answers to life science companies on how to integrate sustainability into their business model.